7. Site of mutation in germline (g) or somatic (s)BRCA .

No. of patients	BRCAmutation type	Tumor type	Fluzoparib dose	Site of mutation	Clinically important	PFS (month)
gBRCA, germline breast cancer susceptibility gene; OC, ovarian cancer; BC, breast cancer; PFS, progression-free survival; *, BRCA somatic mutation detected by next generation sequencing using plasma ctDNA; #, patients still on treatment.
03002	gBRCA1	OC	80 mg bid	c.5332+1delG	Pathogenic	2.0
02041#	gBRCA1	OC	80 mg bid	c.5470_5477delATTGGGCA	Pathogenic	23.2
01024	gBRCA2	OC	100 mg bid	c.6405_6409delCTTAA	Pathogenic	8.9
03004	gBRCA1	OC	100 mg bid	c.2572C>T	Pathogenic	12.6
01025	gBRCA1	OC	100 mg bid	c.5035delC	Pathogenic	2.0
02017	gBRCA1	OC	120 mg qd	NM_007294.3:c.3756_3759delp.Leu 1252fs	Likely pathogenic	9.3
03010	gBRCA1	OC	150 mg bid	c.5470_5477delATTGGGCA	Pathogenic	1.9
	gBRCA2			c.3007C>G	Uncertain significance
03011#	gBRCA2	OC	150 mg bid	c.9117G>A	Pathogenic	16.1
03009	gBRCA1	OC	150 mg bid	c.5407-1G>A	Pathogenic	1.0
	gBRCA2			c.4599A>C, c.6325G>A	Likely benign
06001#	gBRCA1	OC	150 mg bid	c.66dupA	Pathogenic	17.0
06005	gBRCA1	OC	150 mg bid	c.5030_5033delCTAA	Pathogenic	7.6
02021	gBRCA1	BC	160 mg qd	rs3092994;c.4308T>C;c.3113A>G;c.2612C>T;c.2082C>T	Benign	14.0
	gBRCA2			c.7242A>G;c.7397T>C; c.4563A>G;	Benign
	gBRCA2			c.4240delA	Pathogenic
	sBRCA2*			c.7230del	Pathogenic
02025#	gBRCA2	BC	60 mg bid	c.6513G>C;c.7397T>C	Benign	28.0
	sBRCA1*			c.670+2T>A	Pathogenic